Dr. Lin Elected as Surgical Oncology Co-Chair

Effective July 1 2022, Dr. Daniel W. Lin, Vice Chair of Research, was elected by the NCI Genitourinary Cancers Steering Community as Surgical Oncology Co-Chair of the GUSC. The GUSC’s mission is to address and discuss the design, prioritization, and evaluation concepts for phase 2 and phase 3 clinical trials within genitourinary cancer. In order to ensure that their goals and mission of the organization are met, the GUSC has different task forces that meet monthly to discuss concepts, and provide advisory into three different disease subtypes which consist of: prostate, bladder, and renal. Additionally, the GUSC also holds periodic Clinical Trial Planning Meetings which then discuss topics such as: Small Renal Masses and Early Stage Renal Cell Carcinoma, Novel Therapeutics for Non-Muscle Invasive Bladder Cancer, and Advanced Renal Cell Cancer in order to focus on specific clinical trial topics. Dr. Lin will hold the position of Surgical Oncology Co-Chair until reelections are held in 2025. Click here to see Dr. Lin's feature on the huddle.